Alan Rosales

Scientist i, Gene Therapy R & d @Sarepta Therapeutics

Columbus, OH, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Nov 2024 — Present

Scientist i, Gene Therapy R & d @Sarepta Therapeutics

View department →

Columbus, OH, US

Gene Therapy R&D Group:I focus on target discovery, characterization of preclinical animal models of neuromuscular and cardiac diseases, and demonstration of the mechanism of action of gene therapies through in vitro and in vivo preclinical studies. I also assist in designing and executing critical preclinical studies that evaluate efficacy and safety, helping to bridge the gap between early research and clinical application.

EDUCATION

N/A

Duke University

Doctor of Philosophy, Biomedical Engineering

2006 — 2010

Medgar Evers College Preparatory School

High School Diploma

2010 — 2014

University of Rochester

Bachelor of Science, Biomedical Engineering

2017 — 2019

The City College of New York

Master of Science, Biomedical Engineering

SKILLS

StatisticsGeneticsImmunoprecipitationNucleofectionMicrosoft WordAnimal WorkViral VectorsTransfectionMammalian Cell CulturingC++Protein AssaysData AnalysisImagejClc Sequence ViewerBacterial CulturingElisaMatlabGel ElectrophoresisImage AnalysisResearchMicrosoft PowerpointBsl2+ TrainedDna SequencingIr SpectroscopyTeamworkPcrVirus CultureJavaLaboratory TechniquesLeadershipBacterial TransformationMouse ModelsRna IsolationLaboratory Animal MedicineLentivirusTransductionCell CultureVirologyTransgenic MiceBacterial Culture

ABOUT ALAN ROSALES

I am currently a Scientist I in the Gene Therapy R&D group at Sarepta Therapeutics. I earned a PhD in Biomedical Engineering from Dr. Aravind Asokan’s Lab at Duke University, where my research was dedicated to pioneering advancements in gene therapy through the evolution of adeno-associated viruses (AAV). One focus of my work was engineering novel AAV variants capable of robust and effective gene transfer across multiple species, with a specific emphasis on kidney-targeted therapies. These efforts led to the discovery of new AAV variants with enhanced capabilities in diverse kidney models, ranging from murine to porcine, human kidney organoids, and nonhuman primate kidneys.My role extended beyond benchwork; I conceptualized, designed, and executed both in vivo and in vitro studies, contributing to a deeper understanding of AAV-mediated gene transfer. This research spanned multi-scale model systems, from organoids to large animal models, enabling translational insights that bridged the gap between laboratory findings and clinical application.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.